Herbal Medicines for Long COVID: A Phase 2 Pilot Clinical Study DOI Open Access
Tae-Hun Kim, Ji‐Won Yoon, Sang‐Hyun Kim

и другие.

Опубликована: Янв. 23, 2024

Background: Infections of Coronavirus Disease-2019 (COVID-19) can cause long-term effects known as long COVID. This pilot study aimed to evaluate the feasibility a clinical well efficacy and safety traditional East Asian herbal medicines in alleviating fatigue cognitive dysfunction “brain fog” patients with Methods: prospective investigated use three types medicines, Bojungikki-tang (BIT), Kyungok-go (KOG), Cheonwangbosim-dan (CBD), for 12-week period potential treatments Forty-five COVID were recruited, one drugs was given based on patient’s symptoms pattern identification. The effect medications function outcomes assessed over 36-week period, patient adherence closely monitored. Results: After 12 weeks drug administration, improved significantly across all groups, treatment success rates 80%, 53.33%, 46.67% BIT, KOG, CBD respectively. However, showed less improvement, 40%, 46.67%, 13.33% All adverse events reported mild unrelated medication. design found be feasible high medication adherence. Conclusions: demonstrated conducting trial treat like fog.”

Язык: Английский

Herbal Medicines for Long COVID: A Phase 2 Pilot Clinical Study DOI Open Access
Tae-Hun Kim, Ji‐Won Yoon, Sang‐Hyun Kim

и другие.

Опубликована: Янв. 23, 2024

Background: Infections of Coronavirus Disease-2019 (COVID-19) can cause long-term effects known as long COVID. This pilot study aimed to evaluate the feasibility a clinical well efficacy and safety traditional East Asian herbal medicines in alleviating fatigue cognitive dysfunction “brain fog” patients with Methods: prospective investigated use three types medicines, Bojungikki-tang (BIT), Kyungok-go (KOG), Cheonwangbosim-dan (CBD), for 12-week period potential treatments Forty-five COVID were recruited, one drugs was given based on patient’s symptoms pattern identification. The effect medications function outcomes assessed over 36-week period, patient adherence closely monitored. Results: After 12 weeks drug administration, improved significantly across all groups, treatment success rates 80%, 53.33%, 46.67% BIT, KOG, CBD respectively. However, showed less improvement, 40%, 46.67%, 13.33% All adverse events reported mild unrelated medication. design found be feasible high medication adherence. Conclusions: demonstrated conducting trial treat like fog.”

Язык: Английский

Процитировано

1